Life Sciences Foundation Appoints Carl Feldbaum as New

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Life Sciences Foundation Appoints Carl Feldbaum as New Board Chair

SAN FRANCISCO, July 2, 2014 (GLOBE NEWSWIRE) -- The Life Sciences Foundation, a nonprofit organization dedicated to biotech history, has appointed Carl Feldbaum as the new interim board chair. Feldbaum replaces G. Steven Burrill. The LSF board accepted Burrill's resignation today, and expressed their gratitude for his years of leadership to the organization.

Carl Feldbaum has served as a director of the Life Sciences Foundation since 2011. Feldbaum also serves on the boards of BIO Ventures for Global Health, Actelion Pharmaceuticals Ltd., and Exelixis. Previously, he served as founding president of the Biotechnology Industry Organization (BIO) from 1993 until his retirement in 2005.

"Carl has been an invaluable leader and contributor to LSF's board and is a trusted counselor to the Foundation staff," says Heather Erickson, President and CEO of the Life Sciences Foundation.

Five years ago, G. Steven Burrill was part of a small group of biotech leaders who came together to discuss the importance of capturing the great stories and lessons of the biotech pioneers for future generations. From this meeting, the Life Sciences Foundation was formed in 2010.

According to Erickson, "Steve's history in the biotech industry reaches back over 40 years. He's witnessed and been involved in the formation and growth of biotech's earliest companies. The Life Sciences Foundation has greatly benefited from his perspective and passion for the biotech industry."

The Life Sciences Foundation educates and inspires curious minds with the history and continuing significance of biotechnology. The foundation is collecting, preserving and sharing firsthand information about the people, organizations and discoveries that define biotechnology and continue to shape the world in which we live.

More information is available at biotechhistory.org .

Press Contact: Donna Lock Phone: 415-798-2090 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 445

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 222

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 198

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 216

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 163

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 152

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 306

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 392

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 410

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 314

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights on Stocks: Applied Materials, Coupang, and Starbucks

Updated Category News Views 176

Market Highlights from CNBC's Final Trades In the latest episode of CNBC's “Halftime Report Final Trades,” Jim Lebenthal from Cerity Partners highlighted a compelling trade with Applied Materials, Inc. (NASDAQ: AMAT), suggesting it's one to watch closely in the current market environment. Applied Materials: Recent Developments Recently, applied materials found itself...

Continue Reading
Investors Urged to Take Action on Biohaven Ltd. Lawsuit

Updated Category News Views 101

Key Details for Biohaven Ltd. Investors Attention investors! If you've acquired securities of Biohaven Ltd. between certain dates, it's crucial to know about an ongoing class action lawsuit that may affect you. Now is the time to ensure your rights are protected. Why You Should Act Now The Rosen Law Firm has announced an important deadline for those who purchased Biohaven...

Continue Reading
ProPhase Labs Inc. Growth Update: Strategies & Innovations

Updated Category News Views 141

ProPhase Labs Inc. Update Overview Diamond Equity Research has recently published a significant update on ProPhase Labs Inc. (NASDAQ: PRPH), shedding light on the company’s strategic initiatives and innovations. This analysis explores ProPhase's evolving business model, its position within the industry, financial performance, and potential market risks. Growth...

Continue Reading
Donaldson Company Reports Record Sales and Ambitious 2026 Goals

Updated Category News Views 216

Donaldson Company Reports Outstanding Results for Fourth Quarter Donaldson Company (NYSE: DCI) has recently provided an impressive overview of its fourth-quarter and full-year fiscal 2025 performance. The company reported remarkable sales figures and notable earnings that reflect its ability to navigate market challenges effectively. With guidance for fiscal 2026 now in...

Continue Reading
Brandywine Realty Trust's 2024 Financial Performance Revealed

Updated Category News Views 189

Brandywine Realty Trust Reports Impressive Results for 2024 In a recent announcement, Brandywine Realty Trust (NYSE: BDN) showcased its financial and operational results for 2024, indicating strong performance across several metrics. As the company evaluates these results, it prepares for an even more promising outlook in 2025. Remarkable Achievements in 2024 Operational...

Continue Reading